Hazlett, Burt & Watson’s AbbVie ABBV Stock Holding History

Hazlett, Burt & Watson’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.89M	Buy	11,476 +739	+7%	+$159K	0.77%	29
2026 Q1	$2.34M	Buy	10,737 +6	+0.1%	+$1.33K	0.73%	30
2025 Q4	$2.45M	Buy	10,731 +387	+4%	+$88.2K	0.78%	27
2025 Q3	$2.39M	Buy	10,344 +756	+8%	+$154K	0.85%	26
2025 Q2	$1.78M	Buy	9,588 +111	+1%	+$20.6K	0.73%	35
2025 Q1	$1.99M	Buy	9,477 +200	+2%	+$38.9K	0.89%	21
2024 Q4	$1.65M	Sell	9,277 -139	-1%	-$25.6K	0.73%	30
2024 Q3	$1.86M	Buy	9,416 +62	+0.7%	+$11.6K	0.85%	23
2024 Q2	$1.6M	Buy	9,354 +4,144	+80%	+$686K	0.83%	27
2024 Q1	$947K	Buy	5,210 +56	+1%	+$9.65K	0.57%	35
2023 Q4	$798K	Hold	5,154	–	–	0.54%	38
2023 Q3	$769K	Buy	5,154 +116	+2%	+$17K	0.57%	31
2023 Q2	$678K	Buy	5,038 +5	+0.1%	+$733	0.51%	31
2023 Q1	$802K	Buy	5,033 +188	+4%	+$28.7K	0.66%	27
2022 Q4	$780K	Sell	4,845 -235	-5%	-$36K	0.69%	27
2022 Q3	$682K	Buy	5,080 +7	+0.1%	+$1K	0.66%	32
2022 Q2	$777K	Buy	5,073 +6	+0.1%	+$917	0.71%	28
2022 Q1	$822K	Buy	+5,067	New	+$736K	0.65%	31

Other funds holding ABBV

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Hazlett, Burt & Watson's ABBV Position: Q2 2026 in Review

Hazlett, Burt & Watson increased its AbbVie (ABBV) stake by 6.9% in Q2 2026, buying an estimated $159K and bringing the position to 11,476 shares worth $2.89M. The position accounts for 0.77% of the portfolio, ranked #29.

Hazlett, Burt & Watson first reported a position in ABBV in Q1 2022 and has held it in 18 quarters since. 4,221 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

Hazlett, Burt & Watson held 11,476 shares of AbbVie worth $2.89M as of Q2 2026.
Hazlett, Burt & Watson bought 739 AbbVie shares in Q2 2026, an estimated $159K.
AbbVie made up 0.77% of Hazlett, Burt & Watson's portfolio in Q2 2026, its #29 holding.
Hazlett, Burt & Watson first reported a position in AbbVie in Q1 2022 and has held it in 18 quarters since.
4,221 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Hazlett, Burt & Watson's 13F filing for Q2 2026, filed 30 Jul 2026.